| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Smith Hunter C | Chief Financial Officer | C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON | /s/ Stephen Vander Stoep, attorney-in-fact for Hunter C. Smith | 19 Feb 2026 | 0001636385 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RYTM | Common Stock | Sale | $119,298 | -1,200 | -1% | $99.42 | 117,266 | 17 Feb 2026 | Direct | F1, F2 |
| transaction | RYTM | Common Stock | Sale | $20,104 | -200 | -0.17% | $100.52 | 117,066 | 17 Feb 2026 | Direct | F1, F3 |
| transaction | RYTM | Common Stock | Sale | $91,530 | -900 | -0.77% | $101.70 | 116,166 | 17 Feb 2026 | Direct | F1, F4 |
| transaction | RYTM | Common Stock | Sale | $110,110 | -1,069 | -0.92% | $103.00 | 115,097 | 17 Feb 2026 | Direct | F1, F5 |
| transaction | RYTM | Common Stock | Sale | $20,768 | -200 | -0.17% | $103.84 | 114,897 | 17 Feb 2026 | Direct | F1 |
| transaction | RYTM | Common Stock | Sale | $131,153 | -1,308 | -1.1% | $100.27 | 113,589 | 19 Feb 2026 | Direct | F1, F6 |
| transaction | RYTM | Common Stock | Sale | $170,755 | -1,692 | -1.5% | $100.92 | 111,897 | 19 Feb 2026 | Direct | F1, F7 |
| transaction | RYTM | Common Stock | Sale | $81,676 | -800 | -0.71% | $102.10 | 111,097 | 19 Feb 2026 | Direct | F1, F8 |
| transaction | RYTM | Common Stock | Sale | $60,420 | -585 | -0.53% | $103.28 | 110,512 | 19 Feb 2026 | Direct | F1, F9 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on February 28, 2025. |
| F2 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.25 to $99.87 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.34 to $100.70 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.45 to $101.88 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $102.52 to $103.43 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $99.55 to $100.54 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $100.57 to $101.55 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F8 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $101.57 to $102.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F9 | The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $103.09 to $103.50 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |